Boston Scientific Reports Strong Q4 and Full Year 2024 Results and Provides 2025 Guidance

Details

GAAP net income for Q4 was $566 million, or $0.38 per share, and $1.853 billion for the full year, or $1.25 per share. The company also highlighted significant clinical achievements and strategic acquisitions, including the FARAPULSE Pulsed Field Ablation System and acquisitions of Axonics, Inc., Cortex, Inc., Bolt Medical, Inc., and Intera Oncology Inc. Boston Scientific provided guidance for 2025, estimating net sales growth of approximately 12.5 to 14.5 percent on a reported basis and adjusted EPS of $2.80 to $2.87.

Items reported

Exhibits (1)

About Boston Scientific Corporation

Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.